What is Paradigm Medical Ind?
develops, manufactures, sells, and markets medical devices for the early detection of glaucoma and other eye disorders in the United States.
PDMI · Verdict
Limited reward · elevated risk
PDMI's standout is volatility; growth and cash flow weigh on the picture.
Based on 88% data coverage
PDMI · Verdict
Above average
Rev -15.0% CAGR · earnings -35.0%
-96% free-cash-flow margin
Current ratio 0.20
-61% net margin · 0% ROE
Model-based scoring. For information only — not financial advice.
develops, manufactures, sells, and markets medical devices for the early detection of glaucoma and other eye disorders in the United States. The company offers P-2000 biometric analyzer A-scans and P-2500 A-scans/pachymeters; P2700 A/B and P37-II A/B scans; blood flow analyzers for the detection and management of glaucoma and other retinal vascular disorders; P2200 pachymeter and P-2500 A-scan/pachymeters; and LD 500 and LD700 autoperimeters. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 649.76K.
The scoring profile indicates weak reward characteristics across most factors, including valuation and momentum. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.
For informational purposes only. Not financial advice.